Skip to main
RNTX

RNTX Stock Forecast & Price Target

RNTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Rein Therapeutics Inc. is recognized for its innovative approach to developing therapies for orphan pulmonary and fibrosis indications, boasting two Phase 2-ready clinical assets with promising trial results. Notable findings from the LTI-03 trial reveal increased sRAGE levels in recipients, indicating positive pharmacodynamic activity and bolstering the potential efficacy of its product candidates. The company's robust pipeline and the opportunity to address significant market needs in areas lacking effective treatments present a favorable risk-reward profile that positions Rein Therapeutics for potential outperformance in the coming year.

Bears say

Rein Therapeutics Inc. has experienced a significant decline in its stock value, reflecting a 50% drop year to date in 2025, which starkly contrasts with the 3.5% increase in the XBI index. This downturn has been largely attributed to the company’s decision to pause clinical trial enrollments in the U.S., leading to heightened uncertainty among investors regarding the future of its product candidates. Additionally, concerning data related to lower sRAGE levels, which have been correlated with poor survival rates in patients with Idiopathic Pulmonary Fibrosis, may further dampen confidence in the company's therapeutic prospects and overall viability.

RNTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Rein Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Rein Therapeutics Inc (RNTX) Forecast

Analysts have given RNTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, RNTX has a Strong Buy consensus rating as of Jan 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Rein Therapeutics Inc (RNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.